Omaha, NENCT07688187Now EnrollingIRB Ready

Clear Cell Renal Cell Carcinoma Clinical Trial in Omaha, NE

Access cutting-edge clear cell renal cell carcinoma treatment through this phase 1 clinical trial at a research site in Omaha. Study-provided care at no cost to qualified participants.

Sponsored by PeptiDream Inc.

Quick Self-Assessment

See if you qualify for this Omaha location

Preparing your pre-screening questions…

Expert Care in Omaha

Access clear cell renal cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related clear cell renal cell carcinoma treatment provided free

Apply for This Omaha Location

Check if you qualify for this clear cell renal cell carcinoma clinical trial in Omaha, NE

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Omaha

    Convenient for NE residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Omaha site if eligible
  4. 4Begin participation

About This Clear Cell Renal Cell Carcinoma Study in Omaha

This is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-32766T) in adult patients with relapsed or refractory Carbonic Anhydrase IX (CA9)-expressing clear cell renal cell carcinoma (ccRCC). The primary objective is to evaluate the safety and tolerability of PD-32766T, and to characterize its pharmacokinetics and preliminary antitumor activity. Participants will first undergo imaging with PD-32766D to assess CA9 expression. Subjects with positive tumor uptake will be eligible to receive PD-32766T. In Phase 1a, PD-32766T will be administered in an escalating dose levels and schedule determined according to protocol and Safety Review Committee recommendations. In Phase 1b, participants will receive PD-32766T at the recommended dose and schedule identified from Phase 1a to further evaluate safety, tolerability, and preliminary efficacy. A total of up to 60 participants will be enrolled in the study.

Sponsor: PeptiDream Inc.

Who Can Participate

Inclusion Criteria

Male or female participants aged ≥18 years.
Participants with confirmed diagnosis of ccRCC will be included based on the following characteristics:
Histological confirmed locally advanced, unresectable, or metastatic ccRCC, after all available standard therapy.
Presence of evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) guideline (defined by RECIST v1.1).
Presence of positive tumor uptake
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1.
The participant's with adequate organ function
Life expectancy of at least 12 weeks as assessed by the Investigator.

Exclusion Criteria

Concurrent serious (as determined by the Investigator), uncontrolled medical conditions, or life-threatening or other significant comorbid conditions.
Any chemotherapy, radiotherapy, immunotherapy, major surgery, biologic, investigational or hormonal therapy for treatment of solid tumors within 28 days.
Participants who have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy.
Administration of a radiopharmaceutical with therapeutic intent within a period of 6 months.
Any previous CA9 targeting treatment.
Known hypersensitivity to the active substance or to any of the excipients of the PD-32766D and or T.
Clinically unstable CNS tumor at the time of screening.
History of bowel perforation or bowel infarction, history of active stomach or duodenum ulcer or fistula in the last 2 years, history of gastroesophageal reflux disease or enterocolitis Grade ≥3 according to NCI-CTCAE and/or known active gastrointestinal infection, any unresolved prior radiation-induced gastrointestinal injury.
Acute infection requiring IV antibiotics, antivirals, or antifungals within 14 days prior to the initiation of treatment (oral treatment are allowed).
Pregnant or breastfeeding women.
Known active infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
Have been diagnosed with another primary malignancy.
Have significant, uncontrolled, or active cardiovascular disease
Bladder outflow obstruction or unmanageable urinary incontinence.
Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
Any major surgery within 12 weeks before enrolment.
History of psychiatric illness or social situations likely to interfere with ability to comply with protocol required assessment or give informed consent.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Omaha?

Yes, this clinical trial (NCT07688187) has an active research site in Omaha, NE that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Clear Cell Renal Cell Carcinoma Treatment Options in Omaha, NE

If you're searching for clear cell renal cell carcinoma treatment options in Omaha, NE, this clinical trial (NCT07688187) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Omaha research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced clear cell renal cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all clear cell renal cell carcinoma clinical trials near you to find additional studies recruiting in your area.

More Kidney Cancer Trials in Omaha, NE

See all kidney cancer clinical trials recruiting in Omaha — not just this study.

Browse Kidney Cancer Trials in Omaha →

Browse More Trials by Condition

Kidney Cancer TrialsAll Conditions →

Ready to Join in Omaha?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Omaha, NE